| scholarly article | Q13442814 |
| P2093 | author name string | Jürgen Löhler | |
| Wolfgang Deppert | |||
| Christina Heinlein | |||
| Genrich V Tolstonog | |||
| Frauke Krepulat | |||
| Daniel Speidel | |||
| P2860 | cites work | Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome | Q35829654 |
| Probing p53 biological functions through the use of genetically engineered mouse models | Q36204567 | ||
| The large T antigen of simian virus 40 binds and inactivates p53 but not p73. | Q45751922 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carcinogenesis | Q1637543 |
| P304 | page(s) | 1701-1709 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis | |
| P478 | volume | 122 |
| Q34618971 | A rapid and optimization-free procedure allows the in vivo detection of subtle cell cycle and ploidy alterations in tissues by flow cytometry |
| Q36629345 | An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses |
| Q83729340 | Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms |
| Q37665460 | CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo |
| Q53287381 | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. |
| Q38934976 | Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination |
| Q34965421 | Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma |
| Q35238838 | Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells |
| Q89805344 | Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis |
| Q82852435 | Genotoxic exposure: novel cause of selection for a functional ΔN-p53 isoform |
| Q52647660 | Identification of p53 and its isoforms in human breast carcinoma cells. |
| Q41924363 | Immunotherapy of WAP-TNP mice with early stage mammary gland tumors |
| Q34123850 | Impaired CK1 delta activity attenuates SV40-induced cellular transformation in vitro and mouse mammary carcinogenesis in vivo |
| Q39294303 | Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression |
| Q33682960 | Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation |
| Q33399356 | Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q38959098 | Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice |
| Q35729171 | Mutant p53 protein expression and antioxidant status deficiency in breast cancer |
| Q41490261 | Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells |
| Q36293880 | Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). |
| Q37903701 | Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis |
| Q38417021 | New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer |
| Q52584348 | Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. |
| Q37273304 | Recent advances in p53 research: an interdisciplinary perspective. |
| Q37002268 | Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations |
| Q37662081 | T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy. |
| Q26772237 | The Contrived Mutant p53 Oncogene - Beyond Loss of Functions |
| Q42397956 | The Expression Levels of XLF and Mutant P53 Are Inversely Correlated in Head and Neck Cancer Cells. |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q89460168 | The role of TP53 gain-of-function mutation in multifocal glioblastoma |
| Q34153014 | The role of mutant p53 in human cancer |
| Q47742599 | Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q33668830 | Tumorigenic WAP-T Mouse Mammary Carcinoma Cells: A Model for a Self-Reproducing Homeostatic Cancer Cell System |
| Q37802195 | Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies |
| Q38205099 | Unravelling mechanisms of p53-mediated tumour suppression |
| Q37832072 | p53 and its mutants in tumor cell migration and invasion |
Search more.